Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fran E Cook-Bolden

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
The Journal of Dermatological Treatment|November 16, 2022
Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skinEmil A Tanghetti, Joshua A Zeichner, Michael Gold, et al.
The Journal of Clinical and Aesthetic Dermatology|September 18, 2023
Influence of Season on Efficacy and Tolerability of Tazarotene 0.045% Lotion for the Treatment of AcneJerry Tan, Zoe D Draelos, Melinda J Gooderham, et al.
JAMA Dermatology|April 29, 2026
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A ReviewSamip Sheth, Joseph F Merola, Brittany N Weber, et al.
American Journal of Clinical Dermatology|November 1, 2025
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 WeeksAndrew F Alexis, Michael Bukhalo, Fran E Cook-Bolden, et al.
Journal of Drugs in Dermatology : JDD|September 21, 2018
Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical TrialsAngela Moore, Lawrence J Green, Suzanne Bruce, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
The Journal of Dermatological Treatment|November 16, 2022
Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skinEmil A Tanghetti, Joshua A Zeichner, Michael Gold, et al.
The Journal of Clinical and Aesthetic Dermatology|September 18, 2023
Influence of Season on Efficacy and Tolerability of Tazarotene 0.045% Lotion for the Treatment of AcneJerry Tan, Zoe D Draelos, Melinda J Gooderham, et al.
JAMA Dermatology|April 29, 2026
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A ReviewSamip Sheth, Joseph F Merola, Brittany N Weber, et al.
American Journal of Clinical Dermatology|November 1, 2025
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 WeeksAndrew F Alexis, Michael Bukhalo, Fran E Cook-Bolden, et al.
Journal of Drugs in Dermatology : JDD|September 21, 2018
Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical TrialsAngela Moore, Lawrence J Green, Suzanne Bruce, et al.
Pageof 4